CA1341482C
(en)
*
|
1984-10-31 |
2005-05-10 |
Paul A. Luciw |
Process for preparing fragments of aids-associated retroviruses
|
US5008182A
(en)
*
|
1986-01-10 |
1991-04-16 |
Cetus Corporation |
Detection of AIDS associated virus by polymerase chain reaction
|
EP0252940A4
(de)
*
|
1985-12-05 |
1989-07-27 |
Hutchinson Fred Cancer Res |
Antisense-rna zur behandlung von retroviralen krankheiten.
|
US5637573A
(en)
*
|
1986-05-23 |
1997-06-10 |
Agrawal; Sudhir |
Influenza virus replication inhibiting oligonucleotide analogues and their pharmaceutical compositions
|
US5079351A
(en)
*
|
1986-11-26 |
1992-01-07 |
Cetus Corporation |
Oligonucleotides and kits for detection of htlvi and htlvii viruses by hybridization
|
US5268268A
(en)
*
|
1986-11-26 |
1993-12-07 |
Hoffmann-La Roche Inc. |
Detection of HTLVI and HTLVII viruses by hybridization
|
US5110802A
(en)
*
|
1987-07-14 |
1992-05-05 |
City Of Hope |
Oligonucleotide phosphonates and method of inhibiting a human immunodeficiency virus in vitro utilizing said oligonucleotide phosphonates
|
JP3019994B2
(ja)
|
1987-11-30 |
2000-03-15 |
ユニバーシティ オブ アイオワ リサーチ ファウンデーション |
新規なオリゴデオキシヌクレオチド、それを使用した標的遺伝子の発現をブロックする方法、及び新規なオリゴデオキシヌクレオチド並びにそれを使用した標的遺伝子の発現を阻止する方法
|
US5104791A
(en)
*
|
1988-02-09 |
1992-04-14 |
E. I. Du Pont De Nemours And Company |
Particle counting nucleic acid hybridization assays
|
US5580761A
(en)
*
|
1988-02-16 |
1996-12-03 |
Greatbatch Gen-Aid Ltd. |
Method of conferring resistance to immunodeficiency viral infection
|
EP0331939B1
(de)
*
|
1988-02-16 |
2001-11-14 |
Greatbatch Gen-Aid, Ltd |
Modifizierte Zellen mit Resistenz gegen Retroviralinfektionen
|
DE68925278T2
(de)
*
|
1988-02-26 |
1996-09-19 |
Worcester Found Ex Biology |
Hemmung von htlv-iii durch exogene oligonukleotide
|
US5278302A
(en)
*
|
1988-05-26 |
1994-01-11 |
University Patents, Inc. |
Polynucleotide phosphorodithioates
|
US5750666A
(en)
*
|
1988-05-26 |
1998-05-12 |
Competitve Technologies, Inc. |
Polynucleotide phosphorodithioate compounds
|
US5602244A
(en)
*
|
1988-05-26 |
1997-02-11 |
Competitive Technologies, Inc. |
Polynucleotide phosphorodithioate compounds
|
EP0424473B1
(de)
*
|
1988-07-05 |
1996-05-08 |
Baylor College Of Medicine |
Verfahren zur identifizierung von bakterien
|
GB8827592D0
(en)
*
|
1988-11-25 |
1988-12-29 |
Taniguchi T |
Improvements in & relating to regulation of expression
|
US5176996A
(en)
*
|
1988-12-20 |
1993-01-05 |
Baylor College Of Medicine |
Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
|
US5831066A
(en)
|
1988-12-22 |
1998-11-03 |
The Trustees Of The University Of Pennsylvania |
Regulation of bcl-2 gene expression
|
US5734033A
(en)
*
|
1988-12-22 |
1998-03-31 |
The Trustees Of The University Of Pennsylvania |
Antisense oligonucleotides inhibiting human bcl-2 gene expression
|
US6841541B1
(en)
|
1992-02-21 |
2005-01-11 |
The Trustees Of The University Of Pennsylvania |
Regulation of BCL-2-gene expression
|
US6867195B1
(en)
|
1989-03-21 |
2005-03-15 |
Vical Incorporated |
Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
|
US6214804B1
(en)
|
1989-03-21 |
2001-04-10 |
Vical Incorporated |
Induction of a protective immune response in a mammal by injecting a DNA sequence
|
EP0465529B1
(de)
*
|
1989-03-21 |
1998-04-29 |
Vical, Inc. |
Expression von exogenen polynukleotidsequenzen in wirbeltieren
|
US6673776B1
(en)
|
1989-03-21 |
2004-01-06 |
Vical Incorporated |
Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
|
US5703055A
(en)
*
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
US5693622A
(en)
*
|
1989-03-21 |
1997-12-02 |
Vical Incorporated |
Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
|
ZA902912B
(en)
*
|
1989-04-21 |
1991-01-30 |
Cornell Res Foundation Inc |
Method of inhibiting induction of latent or chronic viral infection
|
US5871958A
(en)
*
|
1989-05-25 |
1999-02-16 |
Duke University |
Mutant rev genes encoding transdominant repressors of HIV replication
|
US6251675B1
(en)
*
|
1989-05-25 |
2001-06-26 |
Duke University |
Methods utilizing mutant rev genes encoding transdominant repressors of HIV replication
|
FR2647810B1
(fr)
*
|
1989-06-02 |
1994-07-22 |
Pasteur Institut |
Amorces oligonucleotidiques pour l'amplification du genome des retrovirus du type hiv-2 et siv, et leurs applications au diagnostic in vitro des infections dues a ces virus
|
US7022814B1
(en)
|
1992-01-21 |
2006-04-04 |
Institut Pasteur And Institut National De La Sante Et De La Recherche Medicale |
Nucleotide sequences derived from the genome of retroviruses of the HIV-1, HIV-2 and SIV type, and their uses in particular for the amplification of the genomes of these retroviruses and for the in vitro diagnosis of the diseases due to these viruses
|
CA2585164C
(fr)
|
1989-06-02 |
2010-02-02 |
Institut Pasteur |
Sequences nucleotidiques issues du genome des retrovirus du type hiv-1, hiv-2 et siv, et leurs applications notamment pour l'amplification des genomes de ces retrovirus et pour lediagnostic in vitro des infections dues a ces virus
|
FR2647809B1
(fr)
*
|
1989-06-02 |
1991-09-20 |
Pasteur Institut |
Amorces oligonucleotidiques pour l'amplification du genome des retrovirus du type hiv-1, hiv-2 et siv, et leurs applications au diagnostic in vitro des infections dues a ces virus
|
AU5931290A
(en)
*
|
1989-06-20 |
1991-01-08 |
Meiogenics, Inc. |
Nuclease resistant, single-stranded, non-naturally occurring nucleic acid molecules
|
EP0483249B1
(de)
*
|
1989-07-18 |
2003-04-23 |
OSI Pharmaceuticals, Inc. |
Methode der veränderung der expression von genen bei der transkription und zum nachweis von chemischen substanzen, die wie modulatoren der genexpression wirken
|
US6203976B1
(en)
*
|
1989-07-18 |
2001-03-20 |
Osi Pharmaceuticals, Inc. |
Methods of preparing compositions comprising chemicals capable of transcriptional modulation
|
US5776502A
(en)
|
1989-07-18 |
1998-07-07 |
Oncogene Science, Inc. |
Methods of transcriptionally modulating gene expression
|
US5580722A
(en)
*
|
1989-07-18 |
1996-12-03 |
Oncogene Science, Inc. |
Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease
|
US5665543A
(en)
|
1989-07-18 |
1997-09-09 |
Oncogene Science, Inc. |
Method of discovering chemicals capable of functioning as gene expression modulators
|
CA2065294A1
(en)
*
|
1989-09-01 |
1991-03-02 |
Bruno Calabretta |
Antisense oligonucleotides to c-abl proto-oncogene
|
DK0500799T3
(da)
*
|
1989-11-16 |
1998-09-14 |
Univ Duke |
Partikel-medieret transformation af animalske vævsceller
|
DE69032134T2
(de)
*
|
1989-12-04 |
1998-07-23 |
Isis Pharmaceuticals Inc |
Antisense oligonukleotidhemmung von papillomavirus
|
US20040142899A1
(en)
*
|
1990-01-11 |
2004-07-22 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
|
US6339066B1
(en)
|
1990-01-11 |
2002-01-15 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
|
US6753423B1
(en)
|
1990-01-11 |
2004-06-22 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
|
US5959096A
(en)
*
|
1992-03-16 |
1999-09-28 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides against human protein kinase C
|
US5248670A
(en)
*
|
1990-02-26 |
1993-09-28 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides for inhibiting herpesviruses
|
US6706694B1
(en)
|
1990-03-21 |
2004-03-16 |
Vical Incorporated |
Expression of exogenous polynucleotide sequences in a vertebrate
|
US20030186913A1
(en)
*
|
1990-03-21 |
2003-10-02 |
Vical Incorporated |
Expression of exogenous polynucleotide sequences in a vertebrate
|
US6228844B1
(en)
|
1991-11-12 |
2001-05-08 |
Vical Incorporated |
Stimulating vascular growth by administration of DNA sequences encoding VEGF
|
EP0537299A1
(de)
*
|
1990-03-29 |
1993-04-21 |
Gilead Sciences, Inc. |
Disulfidkonjugate von oligonukleotid-transportagenten
|
WO1991015226A1
(en)
*
|
1990-04-09 |
1991-10-17 |
The American National Red Cross |
Rejuvenation compositions and methods for their use
|
US5610050A
(en)
*
|
1990-04-20 |
1997-03-11 |
The General Hospital Corporation |
Methods of preventing viral replication
|
HUT65614A
(en)
*
|
1990-04-30 |
1994-07-28 |
Isis Pharmaceuticals Inc |
Process for the oligonucleotide modulation of arachidonic acid metabolism
|
US6034233A
(en)
*
|
1990-05-04 |
2000-03-07 |
Isis Pharmaceuticals Inc. |
2'-O-alkylated oligoribonucleotides and phosphorothioate analogs complementary to portions of the HIV genome
|
CA2082044C
(en)
*
|
1990-05-04 |
1999-08-24 |
David J. Ecker |
Modulation of gene expression through interference with rna secondary structure
|
US5166195A
(en)
*
|
1990-05-11 |
1992-11-24 |
Isis Pharmaceuticals, Inc. |
Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
|
ATE186464T1
(de)
*
|
1990-05-23 |
1999-11-15 |
Isis Pharmaceuticals Inc |
Zusammensetzungen und verfahren zur regulierung der rns-aktivität durch abänderung der rns ''5'- cap-struktur''
|
AU8756691A
(en)
*
|
1990-09-21 |
1992-04-15 |
Johns Hopkins University, The |
Compositions and methods for inhibiting growth or replication of viruses
|
WO1992013092A1
(en)
*
|
1991-01-18 |
1992-08-06 |
Oncogene Science, Inc. |
Methods of transcriptionally modulating expression of hematopoietic growth factor genes
|
WO1992013091A1
(en)
*
|
1991-01-18 |
1992-08-06 |
Oncogene Science, Inc. |
Methods of transcriptionally modulating expression of oncogenes and tumor suppressor genes
|
AU1347292A
(en)
*
|
1991-01-18 |
1992-08-27 |
Oncogene Science, Inc. |
Methods of transcriptionally modulating gene expression of viral genes and other genes
|
AU1469292A
(en)
*
|
1991-01-18 |
1992-08-27 |
Oncogene Science, Inc. |
Methods of transcriptionally modulating expression of growth factor genes and growth factor receptor genes
|
CA2088787A1
(en)
*
|
1991-06-05 |
1992-12-06 |
Ganapathi R. Revankar |
Purine base modified 2'-deoxyribonucleosides, use in triplex forming oligonucleotides and process for preparing the same
|
CA2082411A1
(en)
*
|
1991-06-28 |
1992-12-29 |
Robert D. Rosenberg |
Localized oligonucleotide therapy
|
US5646267A
(en)
*
|
1991-08-05 |
1997-07-08 |
Polish Academy Of Sciences |
Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues
|
US5359052A
(en)
*
|
1991-08-05 |
1994-10-25 |
Polish Academy Of Sciences |
Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates
|
US6369209B1
(en)
|
1999-05-03 |
2002-04-09 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having A-DNA form and B-DNA form conformational geometry
|
US7119184B2
(en)
*
|
1991-08-12 |
2006-10-10 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having A-DNA form and B-DNA form conformational geometry
|
CA2119927A1
(en)
*
|
1991-09-27 |
1993-04-01 |
Michael Y.-X. Ma |
Duplex-forming polynucleotide conjugates
|
ES2103918T3
(es)
*
|
1991-10-17 |
1997-10-01 |
Ciba Geigy Ag |
Nucleosidos biciclicos, oligonucleotidos, procedimiento para su obtencion y productos intermedios.
|
US6335434B1
(en)
|
1998-06-16 |
2002-01-01 |
Isis Pharmaceuticals, Inc., |
Nucleosidic and non-nucleosidic folate conjugates
|
NZ244820A
(en)
*
|
1991-10-25 |
1994-01-26 |
Isis Pharmaceuticals Inc |
Oligonucleotide inhibitor of epstein-barr virus.
|
JP3190042B2
(ja)
*
|
1991-10-31 |
2001-07-16 |
マトリテク インコーポレイテッド |
核マトリックス蛋白液アッセー
|
AU3129993A
(en)
*
|
1991-11-08 |
1993-06-07 |
Massachusetts Institute Of Technology |
Localized oligonucleotide therapy
|
US5274157A
(en)
*
|
1991-11-12 |
1993-12-28 |
Ciba-Geigy Corporation |
Protected formylpentanediols, hydroxymethylpentanediols, process for their preparation and intermediates
|
US5332814A
(en)
*
|
1991-11-12 |
1994-07-26 |
Ciba-Geigy Corporation |
Process for the preparation of carbacyclic nucleosides, and intermediates
|
US8153602B1
(en)
|
1991-11-19 |
2012-04-10 |
Isis Pharmaceuticals, Inc. |
Composition and methods for the pulmonary delivery of nucleic acids
|
AU3249793A
(en)
|
1991-12-24 |
1993-07-28 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulating beta -amyloid
|
WO1993013740A2
(en)
*
|
1991-12-31 |
1993-07-22 |
Worcester Foundation For Experimental Biology |
Antiparasitic oligonucleotides active against drug resistant malaria
|
US5885970A
(en)
*
|
1992-03-16 |
1999-03-23 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides against human protein kinase C
|
US5681747A
(en)
*
|
1992-03-16 |
1997-10-28 |
Isis Pharmaceuticals, Inc. |
Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
|
US5882927A
(en)
*
|
1992-03-16 |
1999-03-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide inhibition of protein kinase C
|
US6537973B1
(en)
|
1992-03-16 |
2003-03-25 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide inhibition of protein kinase C
|
US5916807A
(en)
*
|
1992-03-16 |
1999-06-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides against human protein kinase C
|
US6153599A
(en)
*
|
1992-03-16 |
2000-11-28 |
Isis Pharmaceuticals, Inc. |
Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
|
US6117847A
(en)
*
|
1992-03-16 |
2000-09-12 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for enhanced modulation of protein kinase C expression
|
US5922686A
(en)
*
|
1992-03-16 |
1999-07-13 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide modulation of protein kinase C
|
US5643780A
(en)
*
|
1992-04-03 |
1997-07-01 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulating RNA activity through modification of the 5' cap structure of RNA
|
US5411860A
(en)
*
|
1992-04-07 |
1995-05-02 |
The Johns Hopkins University |
Amplification of human MDM2 gene in human tumors
|
ATE257513T1
(de)
*
|
1992-06-22 |
2004-01-15 |
Matritech Inc |
Neuartige marker maligner zelltypen in der inneren nukleären matrix
|
EP0577558A2
(de)
*
|
1992-07-01 |
1994-01-05 |
Ciba-Geigy Ag |
Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
|
EP0652972B1
(de)
*
|
1992-07-20 |
2004-11-17 |
Isis Pharmaceuticals, Inc. |
Pseudo-halbknoten ausbildende rna durch hybridisierung von antisenseoligonnukleotiden an gezielte rna sekundärstrukturen
|
TW244371B
(de)
*
|
1992-07-23 |
1995-04-01 |
Tri Clover Inc |
|
US6346614B1
(en)
*
|
1992-07-23 |
2002-02-12 |
Hybridon, Inc. |
Hybrid oligonucleotide phosphorothioates
|
US6174868B1
(en)
|
1992-09-10 |
2001-01-16 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of hepatitis C virus-associated diseases
|
US6423489B1
(en)
|
1992-09-10 |
2002-07-23 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of Hepatitis C virus-associated diseases
|
NZ286209A
(en)
*
|
1992-09-10 |
2000-09-29 |
Isis Pharmaceuticals Inc |
Use of HCV RNA anti-sense nucleotide sequences for treating Hepatitis C virus related disease
|
US6995146B2
(en)
|
1992-09-10 |
2006-02-07 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of hepatitis C virus-associated diseases
|
US20040049021A1
(en)
*
|
1992-09-10 |
2004-03-11 |
Anderson Kevin P. |
Compositions and mehtods for treatment of Hepatitis C virus-associated diseases
|
US6391542B1
(en)
|
1992-09-10 |
2002-05-21 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of Hepatitis C virus-associated diseases
|
US5985558A
(en)
*
|
1997-04-14 |
1999-11-16 |
Isis Pharmaceuticals Inc. |
Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
|
US7001759B1
(en)
|
1993-01-26 |
2006-02-21 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for delivery of genetic material
|
US5981505A
(en)
*
|
1993-01-26 |
1999-11-09 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for delivery of genetic material
|
US5593972A
(en)
|
1993-01-26 |
1997-01-14 |
The Wistar Institute |
Genetic immunization
|
DE69434469T2
(de)
*
|
1993-01-26 |
2006-06-14 |
Univ Pennsylvania |
Zusammensetzungen und verfahren zur verabreichung von genetischem material
|
US20040087521A1
(en)
*
|
1993-03-18 |
2004-05-06 |
Merck & Co., Inc. |
Nucleic acid pharmaceuticals-influenza matrix
|
DE59407895D1
(de)
*
|
1993-05-12 |
1999-04-15 |
Novartis Ag |
Nukleoside und Oligonukleotide mit 2'-Ethergruppen
|
EP1624068A1
(de)
*
|
1993-06-01 |
2006-02-08 |
Life Technologies Inc. |
Genetische Impfung mit kationischen Lipidstoffen
|
DE69432635D1
(de)
*
|
1993-07-19 |
2003-06-12 |
Gen Probe Inc |
Oligonukleotide mit wirkung gegen den menschlichen immunodefiziens-virus
|
US5739309A
(en)
*
|
1993-07-19 |
1998-04-14 |
Gen-Probe Incorporated |
Enhancement of oligonucleotide inhibition of protein production, cell proliferation and / or multiplication of infectious disease pathogens
|
US6294664B1
(en)
|
1993-07-29 |
2001-09-25 |
Isis Pharmaceuticals, Inc. |
Synthesis of oligonucleotides
|
US5571902A
(en)
*
|
1993-07-29 |
1996-11-05 |
Isis Pharmaceuticals, Inc. |
Synthesis of oligonucleotides
|
US6001982A
(en)
|
1993-07-29 |
1999-12-14 |
Isis Pharmaceuticals, Inc. |
Synthesis of oligonucleotides
|
AU679566B2
(en)
|
1993-09-03 |
1997-07-03 |
Isis Pharmaceuticals, Inc. |
Amine-derivatized nucleosides and oligonucleosides
|
US6348449B1
(en)
*
|
1993-09-21 |
2002-02-19 |
The Trustees Of The University Of Pennsylvania |
Methods of inducing mucosal immunity
|
US5807838A
(en)
*
|
1994-09-23 |
1998-09-15 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide modulation of multidrug resistance-associated protein
|
US5510239A
(en)
*
|
1993-10-18 |
1996-04-23 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide modulation of multidrug resistance-associated protein
|
DE4338704A1
(de)
*
|
1993-11-12 |
1995-05-18 |
Hoechst Ag |
Stabilisierte Oligonucleotide und deren Verwendung
|
AU697134B2
(en)
*
|
1994-01-26 |
1998-09-24 |
Novartis Ag |
Modified oligonucleotides
|
US6995008B1
(en)
|
1994-03-07 |
2006-02-07 |
Merck & Co., Inc. |
Coordinate in vivo gene expression
|
ATE244723T1
(de)
*
|
1994-04-27 |
2003-07-15 |
Novartis Pharma Gmbh |
Nukleoside und oligonukleotide mit 2'- ethergruppen
|
US6358932B1
(en)
|
1994-05-31 |
2002-03-19 |
Isis Pharmaceticals, Inc. |
Antisense oligonucleotide inhibition of raf gene expression
|
US20030119769A1
(en)
*
|
1994-05-31 |
2003-06-26 |
Monia Brett P |
Antisense oligonucleotide modulation of raf gene expression
|
US6090626A
(en)
*
|
1994-05-31 |
2000-07-18 |
Isis Pharmaceuticals Inc. |
Antisense oligonucleotide modulation of raf gene expression
|
US5744362A
(en)
*
|
1994-05-31 |
1998-04-28 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of raf gene expression
|
US6410518B1
(en)
|
1994-05-31 |
2002-06-25 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide inhibition of raf gene expression
|
US20060142236A1
(en)
*
|
1994-05-31 |
2006-06-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of raf gene expression
|
US5656612A
(en)
*
|
1994-05-31 |
1997-08-12 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of raf gene expression
|
KR100211178B1
(ko)
*
|
1994-05-31 |
1999-07-15 |
파샬 비. 린네 |
라프유전자 발현의 안티센스 올리고뉴클레오티드 조절
|
US5563255A
(en)
*
|
1994-05-31 |
1996-10-08 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of raf gene expression
|
US5691316A
(en)
*
|
1994-06-01 |
1997-11-25 |
Hybridon, Inc. |
Cyclodextrin cellular delivery system for oligonucleotides
|
US20030026782A1
(en)
*
|
1995-02-07 |
2003-02-06 |
Arthur M. Krieg |
Immunomodulatory oligonucleotides
|
US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US5733781A
(en)
*
|
1994-07-19 |
1998-03-31 |
Gen-Probe Incorporated |
Oligonucleotides and methods for inhibiting propagation of human immunodeficiency virus
|
DE4427219A1
(de)
*
|
1994-08-01 |
1996-02-08 |
Max Planck Gesellschaft |
Nukleinsäure zur Initiation der Aktivität von RNase H bzw. reverser Transkriptase
|
EP0774902A1
(de)
*
|
1994-08-10 |
1997-05-28 |
Sidney Altman |
Antisense- und triplextherapeutika und verfahren
|
JPH10505354A
(ja)
*
|
1994-09-02 |
1998-05-26 |
ノバルティス アクチェンゲゼルシャフト |
官能テルピリジン−金属錯体、その製法及びテルピリジン−金属錯体とのオリゴヌクレオチド複合体
|
ATE340866T1
(de)
*
|
1994-10-28 |
2006-10-15 |
Gen Probe Inc |
Zusammensetzungen und verfahren für die gleichzeitige detektion und quantifizierung von einer mehrheit spezifischer nuklein säure sequenzen
|
WO1996024378A2
(en)
|
1995-02-10 |
1996-08-15 |
Worcester Foundation For Biomedical Research, Inc. |
Delivery of exogenous compounds
|
US6117993A
(en)
*
|
1995-05-23 |
2000-09-12 |
Hybridon, Inc. |
Synthons for oligonucleotide synthesis
|
US5750674A
(en)
*
|
1995-05-23 |
1998-05-12 |
Hybridon, Inc. |
Methods and compounds for the stereoselective enrichment of oligonucleotide diastereomers and oligonucleotides thereby produced
|
US5693773A
(en)
*
|
1995-06-07 |
1997-12-02 |
Hybridon Incorporated |
Triplex-forming antisense oligonucleotides having abasic linkers targeting nucleic acids comprising mixed sequences of purines and pyrimidines
|
US5985662A
(en)
*
|
1995-07-13 |
1999-11-16 |
Isis Pharmaceuticals Inc. |
Antisense inhibition of hepatitis B virus replication
|
US5652356A
(en)
*
|
1995-08-17 |
1997-07-29 |
Hybridon, Inc. |
Inverted chimeric and hybrid oligonucleotides
|
US6624293B1
(en)
|
1995-08-17 |
2003-09-23 |
Hybridon, Inc. |
Modified protein kinase A-specific oligonucleotides and methods of their use
|
US7074768B2
(en)
|
1995-08-17 |
2006-07-11 |
Idera Pharmaceuticals, Inc. |
Modified protein kinase A-specific oligonucleotides and methods of their use
|
US5981180A
(en)
*
|
1995-10-11 |
1999-11-09 |
Luminex Corporation |
Multiplexed analysis of clinical specimens apparatus and methods
|
GB9604669D0
(en)
|
1996-03-05 |
1996-05-01 |
Ciba Geigy Ag |
Chemical compounds
|
EP0932698A1
(de)
*
|
1996-03-26 |
1999-08-04 |
Lynx Therapeutics, Inc. |
Oligonukleotide zusammenstellungen zur behandlung von menschlichem melanom
|
US5856099A
(en)
*
|
1996-05-21 |
1999-01-05 |
Isis Pharmaceuticals, Inc. |
Antisense compositions and methods for modulating type I interleukin-1 receptor expression
|
US6776986B1
(en)
|
1996-06-06 |
2004-08-17 |
Novartis Ag |
Inhibition of HIV-1 replication by antisense RNA expression
|
WO1998003646A1
(en)
*
|
1996-07-22 |
1998-01-29 |
Hybridon, Inc. |
Compositions and methods for treating specific gene expression-related diseases and disorders in humans
|
US5856462A
(en)
*
|
1996-09-10 |
1999-01-05 |
Hybridon Incorporated |
Oligonucleotides having modified CpG dinucleosides
|
US5885834A
(en)
*
|
1996-09-30 |
1999-03-23 |
Epstein; Paul M. |
Antisense oligodeoxynucleotide against phosphodiesterase
|
US6001991A
(en)
*
|
1996-10-04 |
1999-12-14 |
Isis Pharmaceuticals Inc. |
Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
|
US6449562B1
(en)
|
1996-10-10 |
2002-09-10 |
Luminex Corporation |
Multiplexed analysis of clinical specimens apparatus and method
|
US6077833A
(en)
*
|
1996-12-31 |
2000-06-20 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
US20040023917A1
(en)
*
|
1996-12-31 |
2004-02-05 |
Bennett C. Frank |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
US6319906B1
(en)
|
1996-12-31 |
2001-11-20 |
Isis Pharmaceuticals |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
US7235653B2
(en)
*
|
1996-12-31 |
2007-06-26 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
WO1998042722A1
(en)
|
1997-03-21 |
1998-10-01 |
President And Fellows Of Harvard College |
Antisense inhibition of angiogenin expression
|
ATE321882T1
(de)
|
1997-07-01 |
2006-04-15 |
Isis Pharmaceuticals Inc |
Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
|
US20070149472A1
(en)
*
|
1997-08-13 |
2007-06-28 |
Mckay Robert |
Antisense oligonucleotide compositions and methods for the modulation of jnk proteins
|
US5877309A
(en)
*
|
1997-08-13 |
1999-03-02 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides against JNK
|
US6809193B2
(en)
|
1997-08-13 |
2004-10-26 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
|
US6133246A
(en)
*
|
1997-08-13 |
2000-10-17 |
Isis Pharmaceuticals Inc. |
Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
|
ES2255732T3
(es)
*
|
1997-08-19 |
2006-07-01 |
Idera Pharmaceuticals, Inc. |
Oligonucleotidos especificos de vih y procedimientos para su utilizacion.
|
US20030036516A1
(en)
*
|
1997-09-10 |
2003-02-20 |
Sudhir Agrawal |
Method for using oligonucleotides having modified cpg dinucleotides
|
US6306831B1
(en)
|
1997-09-12 |
2001-10-23 |
Qik Technologies, Inc. |
Transplacental delivery of oligonucleotides
|
US20040186071A1
(en)
*
|
1998-04-13 |
2004-09-23 |
Bennett C. Frank |
Antisense modulation of CD40 expression
|
US7321828B2
(en)
*
|
1998-04-13 |
2008-01-22 |
Isis Pharmaceuticals, Inc. |
System of components for preparing oligonucleotides
|
EP1080103A4
(de)
*
|
1998-05-21 |
2003-07-02 |
Isis Pharmaceuticals Inc |
Zubereitungen und verfahren zur nicht-parenteralen verabreichung von oligonukleotiden
|
CA2329252A1
(en)
|
1998-05-21 |
1999-11-25 |
Isis Pharmaceuticals Inc. |
Compositions and methods for topical delivery of oligonucleotides
|
DE69932717T2
(de)
|
1998-05-22 |
2007-08-09 |
Ottawa Health Research Institute, Ottawa |
Methoden und produkte zur induzierung mukosaler immunität
|
US6277967B1
(en)
|
1998-07-14 |
2001-08-21 |
Isis Pharmaceuticals, Inc. |
Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages
|
US6867294B1
(en)
|
1998-07-14 |
2005-03-15 |
Isis Pharmaceuticals, Inc. |
Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
|
US6242589B1
(en)
|
1998-07-14 |
2001-06-05 |
Isis Pharmaceuticals, Inc. |
Phosphorothioate oligonucleotides having modified internucleoside linkages
|
US6015676A
(en)
*
|
1998-07-31 |
2000-01-18 |
Epiclone Inc. |
Method for knocking out gene transcripts by covalently binding of an anti-sense probe
|
TR200604211T1
(tr)
*
|
1999-02-12 |
2007-02-21 |
Daiichi Sankyo Company Limiteddaiichi Sankyo Company Limited |
Yeni nükleosid ve oligonükleotid analoglarıYeni nükleosid ve oligonükleotid analogları
|
US6656730B1
(en)
|
1999-06-15 |
2003-12-02 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides conjugated to protein-binding drugs
|
JP4151751B2
(ja)
*
|
1999-07-22 |
2008-09-17 |
第一三共株式会社 |
新規ビシクロヌクレオシド類縁体
|
US20010011126A1
(en)
*
|
1999-09-10 |
2001-08-02 |
Bock Elisabeth Marianne |
Neurogenic compositions and methods
|
AU2001276691A1
(en)
*
|
2000-08-03 |
2002-02-18 |
Matsushita Electric Industrial Co., Ltd. |
Brushless motor and method of manufacturing the brushless motor
|
KR100917101B1
(ko)
*
|
2000-08-04 |
2009-09-15 |
도요 보세키 가부시키가이샤 |
플렉시블 금속적층체 및 그 제조방법
|
US20030096770A1
(en)
*
|
2001-07-11 |
2003-05-22 |
Krotz Achim H. |
Enhancement of the stability of oligonucleotides comprising phosphorothioate linkages by addition of water-soluble antioxidants
|
DK1446162T3
(da)
*
|
2001-08-17 |
2008-12-08 |
Coley Pharm Gmbh |
Kombinationsmotiv-immunstimulatoriske oligonukleotider med forbedret aktivitet
|
JP2005514005A
(ja)
*
|
2001-09-04 |
2005-05-19 |
エクシコン エ/エス |
新規のlna組成物およびその使用
|
EP1470144B1
(de)
*
|
2002-02-01 |
2008-12-03 |
McGILL UNIVERSITY |
Oligonukleotide mit alternierenden segmenten und deren verwendungen
|
US20030191075A1
(en)
*
|
2002-02-22 |
2003-10-09 |
Cook Phillip Dan |
Method of using modified oligonucleotides for hepatic delivery
|
US7807803B2
(en)
|
2002-07-03 |
2010-10-05 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
US7569553B2
(en)
|
2002-07-03 |
2009-08-04 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
US20040053880A1
(en)
*
|
2002-07-03 |
2004-03-18 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
US7605138B2
(en)
*
|
2002-07-03 |
2009-10-20 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
US7576066B2
(en)
*
|
2002-07-03 |
2009-08-18 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
US20040009483A1
(en)
*
|
2002-07-12 |
2004-01-15 |
Ilsley Diane D. |
Method of linear mRNA amplification using total RNA
|
US20050196382A1
(en)
*
|
2002-09-13 |
2005-09-08 |
Replicor, Inc. |
Antiviral oligonucleotides targeting viral families
|
CN1694959B
(zh)
|
2002-09-13 |
2013-09-18 |
雷普利瑟公司 |
非序列互补的抗病毒寡核苷酸
|
US20040219565A1
(en)
|
2002-10-21 |
2004-11-04 |
Sakari Kauppinen |
Oligonucleotides useful for detecting and analyzing nucleic acids of interest
|
US7998492B2
(en)
*
|
2002-10-29 |
2011-08-16 |
Coley Pharmaceutical Group, Inc. |
Methods and products related to treatment and prevention of hepatitis C virus infection
|
AU2003300919A1
(en)
*
|
2002-12-11 |
2004-06-30 |
Coley Pharmaceutical Gmbh |
5' cpg nucleic acids and methods of use
|
WO2004092407A1
(en)
*
|
2003-04-17 |
2004-10-28 |
Genesis Group Inc. |
Pygopus in diagnosis and treatment of cancer
|
US7709207B2
(en)
*
|
2003-05-16 |
2010-05-04 |
Universite Laval |
Method for identifying compounds for treatment of pain
|
US7960355B2
(en)
*
|
2003-05-23 |
2011-06-14 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the modulation of the expression of B7 protein
|
US7897582B2
(en)
*
|
2003-05-23 |
2011-03-01 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
US8188254B2
(en)
*
|
2003-10-30 |
2012-05-29 |
Coley Pharmaceutical Gmbh |
C-class oligonucleotide analogs with enhanced immunostimulatory potency
|
JP2007537167A
(ja)
*
|
2004-05-14 |
2007-12-20 |
ユニヴェルシテ ラヴァル |
ホスホリパーゼcガンマの調節、並びにそれによる疼痛及び侵害受容の制御
|
JP2008509681A
(ja)
*
|
2004-06-09 |
2008-04-03 |
マクギル・ユニバーシテイ |
セノラブディティスエレガンス(caenorhabditiselegans)のアセチルコリン依存性クロライドチャンネルサブユニットをコードするポリヌクレオチド
|
MY159370A
(en)
*
|
2004-10-20 |
2016-12-30 |
Coley Pharm Group Inc |
Semi-soft-class immunostimulatory oligonucleotides
|
EP1907855A4
(de)
*
|
2005-07-12 |
2009-11-11 |
Univ Temple |
Genetische und epigenetische änderungen bei der diagnose und behandlung von krebs
|
US20090093425A1
(en)
*
|
2006-07-12 |
2009-04-09 |
The Regents Of The University Of California |
Transducible delivery of nucleic acids by reversible phosphotriester charge neutralization protecting groups
|
USRE47320E1
(en)
|
2007-11-20 |
2019-03-26 |
Ionis Pharmaceuticals, Inc. |
Modulation of CD40 expression
|
EP3067359A1
(de)
|
2008-09-23 |
2016-09-14 |
Scott G. Petersen |
Selbstfreisetzende biolabile phosphatgeschützte pro-oligos für therapeutika auf oligonukleotidbasis und vermittlung von rna-interferenz
|
US10022454B2
(en)
|
2008-09-23 |
2018-07-17 |
Liposciences, Llc |
Functionalized phosphorodiamites for therapeutic oligonucleotide synthesis
|
US20120128673A1
(en)
|
2009-05-20 |
2012-05-24 |
Schering Corporation |
Modulation of pilr receptors to treat microbial infections
|
WO2011084357A1
(en)
|
2009-12-17 |
2011-07-14 |
Schering Corporation |
Modulation of pilr to treat immune disorders
|
PL3505528T3
(pl)
|
2011-04-21 |
2021-08-02 |
Glaxo Group Limited |
Modulacja ekspresji wirusa zapalenia wątroby typu b (hbv)
|
EP2885313A4
(de)
|
2012-08-20 |
2016-03-09 |
Univ California |
Polynukleotide mit bioreversiblen gruppen
|
JP6794258B2
(ja)
|
2013-09-30 |
2020-12-02 |
ジェロン・コーポレーションGeron Corporation |
オリゴヌクレオチドについてのホスホロジアミデート骨格結合
|
ES2865488T3
(es)
|
2014-09-05 |
2021-10-15 |
Rsem Lp |
Composiciones y métodos para el tratamiento y la prevención de la inflamación
|
CN110023321A
(zh)
|
2016-08-17 |
2019-07-16 |
索尔斯蒂斯生物有限公司 |
多核苷酸构建体
|
EP3645546A4
(de)
|
2017-06-30 |
2021-12-01 |
Solstice Biologics, Ltd. |
Chirale phosphoramidithilfsmittel und verfahren zu ihrer verwendung
|